Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ventricular Arrhythmias
Interventions
spironolactone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Congestive Heart Failure, Diastole
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metabolic Syndrome, Hypertension, Overweight and Obesity
Interventions
Eplerenone, Chlorthalidone with potassium chloride
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
Interventions
2-hydroxybenzylamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Acute Heart Failure
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Duchenne Muscular Dystrophy
Interventions
Eplerenone, Spironolactone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
7 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Kansas + 3 more
Conditions
Acute Decompensated Heart Failure
Interventions
Change of treatment plan
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Results available

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Acute Coronary Syndrome
Interventions
Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
3,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
91
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Tucson, Arizona + 83 more
Conditions
Diabetic Nephropathy
Interventions
spironolactone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Dayton, Ohio
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Heart Failure
Interventions
GUIDED-HF, Standard of Care
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 11 more
Conditions
HIV
Interventions
Eplerenone, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Myocardial Remodeling
Interventions
Eplerenone, Lactose Tablet
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Phenotyping of Autonomous Aldosterone Secretion

NCT03484130
Conditions
Aldosterone Disorder, Adrenal Gland Disease, Blood Pressure
Interventions
Sodium loaded diet, Restricted sodium diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hypertension
Interventions
Para-aminohippuric Acid, Angiotensin II
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Uncontrolled Hypertension
Interventions
BAROSTIM NEO System and Medical Management
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Completed Phase 1Phase 2 Interventional

Fibrosis and the Fontan

NCT04901975
Conditions
Single-ventricle
Interventions
Spironolactone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 6 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Results available

Cardiometabolic Effects of Eplerenone in HIV Infection

NCT02629094
Conditions
Cardiac Steatosis, Hepatic Steatosis
Interventions
Inspra /Eplerenone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Heart Failure
Interventions
HM II (HeartMate II LVAD), OMM (Optimal Medical Management)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
52
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more